Cardiology & Pharmacology
Class I Antiarrhythmics: Sodium Channel Blockers Explained
Sodium channel blockers—designated as Class I antiarrhythmic agents in the Vaughan Williams classification system—play a major role in cardiac electrophysiology. By binding to voltage-gated sodium channels in myocardial tissue, these agents alter the initial depolarizing phase of the cardiac action potential to help suppress ectopic signals and restore sinus rhythm.
Effects of sodium channel blockade on Phase 0 slope and action potential trajectory across Class Ia, Ib, and Ic subclasses.
1. Cellular Mechanism of Action
In cardiac myocytes, Phase 0 is characterized by a rapid influx of sodium ions ( Na+ ) through voltage-gated channels. Class I drugs bind directly to these channels:
- Depression of Phase 0: Slows the rate of phase 0 depolarization ( dV/dtmax ).
- Conduction Velocity: Decreases electrical propagation speed across atrial and ventricular tissues.
- State-Dependence: Binds preferentially to channels in open or inactivated states during rapid tachycardias.
2. Subclasses: Ia, Ib, and Ic
| Subclass | Phase 0 Effect | APD / ERP Effect | Examples | Key Clinical Indications |
|---|---|---|---|---|
| Class Ia | Intermediate | Prolongs | Procainamide, Quinidine, Disopyramide | Atrial fibrillation, VT, WPW syndrome |
| Class Ib | Weak / Rapid kinetics | Shortens | Lidocaine, Mexiletine | Ischemic ventricular arrhythmias |
| Class Ic | Marked / Slow kinetics | No effect | Flecainide, Propafenone | A-fib / flutter in structurally normal hearts |
3. Safety & Clinical Precautions
Careful patient evaluation is mandatory before prescribing Class I agents:
- QRS Widening: Slowed conduction velocity typically manifests as QRS prolongation on an ECG.
- Proarrhythmic Potential: High risks of precipitating or worsening arrhythmias under ischemic conditions.
Contraindication Warning: Class Ic agents (such as Flecainide and Propafenone) are strictly contraindicated in patients with structural heart disease, previous myocardial infarction, or coronary artery disease due to increased mortality risks established in clinical trials (e.g., CAST).
0 Comments